| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients1
* Cancer Research Institute and
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; and
Department of Biochemistry and Division of Brain, Korea 21 Program for Biomedical Science, Korea University College of Medicine, Seoul, Korea
NK cell function in cancer patients is severely impaired, but the mechanism underlying this impairment is not clearly understood. In this study we show evidence that TGF-
1 secreted by tumors is responsible for the poor NK lytic activity via down-regulating an NK-activating receptor, NKG2D. The plasma level of TGF-1 in human lung cancer or colorectal cancer patients was elevated compared with that in normal volunteers, and this elevation was inversely correlated with surface expression of NKG2D on NK cells in these patients. Incubation of NK cells with plasma obtained from cancer patients specifically down-modulated surface NKG2D expression, whereas addition of neutralizing anti-TGF-1 mAbs completely restored surface NKG2D expression. Likewise, incubation of NK cells and lymphokine-activated killer cells with TGF-1 resulted in dramatic reduction of surface NKG2D expression associated with impaired NK cytotoxicity. Modulation of NKG2D by TGF-1 was specific, as expression of other NK receptors, CD94/NKG2A, CD44, CD16, 2B4, or CD56, was not affected by TGF-1. Impaired NK cytotoxicity by TGF-1 was not due to alteration of lytic moieties, such as perforin or Fas, or apoptotic pathway, but, rather, appeared to be due to lack of NKG2D expression. Taken together, our data suggest that impaired NK function in cancer patients can be attributed to down-modulation of activating receptors, such as NKG2D, via secretion of TGF-1.
This article has been cited by other articles:
|
|
 |
|
  R. Trotta, J. D. Col, J. Yu, D. Ciarlariello, B. Thomas, X. Zhang, J. Allard II, M. Wei, H. Mao, J. C. Byrd, et al. TGF-{beta} Utilizes SMAD3 to Inhibit CD16-Mediated IFN-{gamma} Production and Antibody-Dependent Cellular Cytotoxicity in Human NK Cells J. Immunol., September 15, 2008; 181(6): 3784 - 3792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Le Maux Chansac, D. Misse, C. Richon, I. Vergnon, M. Kubin, J.-C. Soria, A. Moretta, S. Chouaib, and F. Mami-Chouaib Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway Int. Immunol., July 1, 2008; 20(7): 801 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Clayton, J. P. Mitchell, J. Court, S. Linnane, M. D. Mason, and Z. Tabi Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression J. Immunol., June 1, 2008; 180(11): 7249 - 7258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Nam, M. Terabe, M. Mamura, M.-J. Kang, H. Chae, C. Stuelten, E. Kohn, B. Tang, H. Sabzevari, M. R. Anver, et al. An Anti-Transforming Growth Factor {beta} Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments Cancer Res., May 15, 2008; 68(10): 3835 - 3843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fichtner-Feigl, M. Terabe, A. Kitani, C. A. Young, I. Fuss, E. K. Geissler, H.-J. Schlitt, J. A. Berzofsky, and W. Strober Restoration of Tumor Immunosurveillance via Targeting of Interleukin-13 Receptor-{alpha}2 Cancer Res., May 1, 2008; 68(9): 3467 - 3475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A Teicher, J. M Yingling, and J. M McPherson TGF{beta} Blockade as Anticancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 71 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Kim, M.-K. Han, and H. E. Broxmeyer 4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells Blood, February 1, 2008; 111(3): 1378 - 1386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Glick, R. Perez-Lorenzo, and J. Mohammed Context-dependent regulation of cutaneous immunological responses by TGF{beta}1 and its role in skin carcinogenesis Carcinogenesis, January 1, 2008; 29(1): 9 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Marusina, S. J. Burgess, I. Pathmanathan, F. Borrego, and J. E. Coligan Regulation of Human DAP10 Gene Expression in NK and T Cells by Ap-1 Transcription Factors J. Immunol., January 1, 2008; 180(1): 409 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Teicher Transforming Growth Factor-{beta} and the Immune Response to Malignant Disease Clin. Cancer Res., November 1, 2007; 13(21): 6247 - 6251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5262 - 5270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Osaki, H. Saito, T. Yoshikawa, S. Matsumoto, S. Tatebe, S. Tsujitani, and M. Ikeguchi Decreased NKG2D Expression on CD8+ T Cell Is Involved in Immune Evasion in Patients with Gastric Cancer Clin. Cancer Res., January 15, 2007; 13(2): 382 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ralainirina, A. Poli, T. Michel, L. Poos, E. Andres, F. Hentges, and J. Zimmer Control of NK cell functions by CD4+CD25+ regulatory T cells J. Leukoc. Biol., January 1, 2007; 81(1): 144 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Eisele, J. Wischhusen, M. Mittelbronn, R. Meyermann, I. Waldhauer, A. Steinle, M. Weller, and M. A. Friese TGF-{beta} and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells Brain, September 1, 2006; 129(9): 2416 - 2425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gasser and D. H. Raulet The DNA damage response arouses the immune system. Cancer Res., April 15, 2006; 66(8): 3959 - 3962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Boissel, D. Rea, V. Tieng, N. Dulphy, M. Brun, J.-M. Cayuela, P. Rousselot, R. Tamouza, P. Le Bouteiller, F.-X. Mahon, et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J. Immunol., April 15, 2006; 176(8): 5108 - 5116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Barao, A. M. Hanash, W. Hallett, L. A. Welniak, K. Sun, D. Redelman, B. R. Blazar, R. B. Levy, and W. J. Murphy Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells PNAS, April 4, 2006; 103(14): 5460 - 5465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mincheva-Nilsson, O. Nagaeva, T. Chen, U. Stendahl, J. Antsiferova, I. Mogren, J. Hernestal, and V. Baranov Placenta-Derived Soluble MHC Class I Chain-Related Molecules Down-Regulate NKG2D Receptor on Peripheral Blood Mononuclear Cells during Human Pregnancy: A Possible Novel Immune Escape Mechanism for Fetal Survival J. Immunol., March 15, 2006; 176(6): 3585 - 3592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Burgess, A. I. Marusina, I. Pathmanathan, F. Borrego, and J. E. Coligan IL-21 Down-Regulates NKG2D/DAP10 Expression on Human NK and CD8+ T Cells J. Immunol., February 1, 2006; 176(3): 1490 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Smyth, M. W. L. Teng, J. Swann, K. Kyparissoudis, D. I. Godfrey, and Y. Hayakawa CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer J. Immunol., February 1, 2006; 176(3): 1582 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells Stem Cells, January 1, 2006; 24(1): 74 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dasgupta, M. Bhattacharya-Chatterjee, B. W. O'Malley Jr, and S. K. Chatterjee Inhibition of NK Cell Activity through TGF-{beta}1 by Down-Regulation of NKG2D in a Murine Model of Head and Neck Cancer J. Immunol., October 15, 2005; 175(8): 5541 - 5550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Lutgendorf, A. K. Sood, B. Anderson, S. McGinn, H. Maiseri, M. Dao, J. I. Sorosky, K. De Geest, J. Ritchie, and D. M. Lubaroff Social Support, Psychological Distress, and Natural Killer Cell Activity in Ovarian Cancer J. Clin. Oncol., October 1, 2005; 23(28): 7105 - 7113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Coudert, J. Zimmer, E. Tomasello, M. Cebecauer, M. Colonna, E. Vivier, and W. Held Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells Blood, September 1, 2005; 106(5): 1711 - 1717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Pilla, P. Squarcina, J. Coppa, V. Mazzaferro, V. Huber, D. Pende, C. Maccalli, G. Sovena, L. Mariani, C. Castelli, et al. Natural Killer and NK-Like T-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96 Cancer Res., May 1, 2005; 65(9): 3942 - 3949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Naiki, K. S. Michelsen, W. Zhang, S. Chen, T. M. Doherty, and M. Arditi Transforming Growth Factor-{beta} Differentially Inhibits MyD88-dependent, but Not TRAM- and TRIF-dependent, Lipopolysaccharide-induced TLR4 Signaling J. Biol. Chem., February 18, 2005; 280(7): 5491 - 5495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Friese, J. Wischhusen, W. Wick, M. Weiler, G. Eisele, A. Steinle, and M. Weller RNA Interference Targeting Transforming Growth Factor-{beta} Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In vivo Cancer Res., October 15, 2004; 64(20): 7596 - 7603. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
